Skip to content

Study · Observational study · n = 60 · 2026

11 results

Use of semaglutide after acute coronary syndrome: an exploratory retrospective study.

Biasin M, Stratinaki M, Cordioli N, Armani I, De Giovanni S, Aletras G, Betta D, Callegarin L, Gambaro A, Morani G

Journal of cardiovascular medicine (Hagerstown, Md.)19 Jan 2026

PMID41703411 (opens in a new tab)DOI10.2459/jcm.0000000000001837 (opens in a new tab)PepBankPUB-41703411
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanObservational studyOther

    In adults with type 2 diabetes after acute coronary syndrome, 81% remained on semaglutide at the first follow-up.

    In plain wordsAfter a heart event, 81% of adults with type 2 diabetes were still taking semaglutide at the first follow-up.

    Peptide
    Semaglutide
    Outcome
    Not applicableTreatment persistence at first follow-up
    Study

    n = 60

    Outcome group
    Treatment adherence and retention · Cardiovascular
    Studied dose
    lowest dose · injectable (83.3%) or oral (16.7%) · 108 ± 39 daysAs given in this study (human).

    Measurements

    Persistence
    81%
    first follow-up

    Source sentences

    Summary
    At the first follow-up (108 ± 39 days), 81% remained on therapy
    2 context sentences
    Summary · context
    We conducted a retrospective, multicenter observational study of adults with T2DM hospitalized for ACS between January 2022 and December 2024 and discharged with a prescription for semaglutide.
    Summary · context
    A total of 60 patients (mean age 61.1 ± 10.8 years, 73% male) were included.
  2. 02HumanObservational studySafety outcome

    In adults with type 2 diabetes after acute coronary syndrome, 15% discontinued semaglutide for gastrointestinal intolerance by the first follow-up.

    In plain wordsAfter a heart event, 15% of adults with type 2 diabetes stopped semaglutide because of stomach and bowel problems.

    Peptide
    Semaglutide
    Outcome
    Not applicableDiscontinuation for gastrointestinal intolerance
    Study

    n = 60

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    lowest dose · injectable (83.3%) or oral (16.7%) · 108 ± 39 daysAs given in this study (human).

    Measurements

    Discontinuation for GI intolerance
    15%
    first follow-up

    Source sentences

    Summary
    discontinuations occurred mainly for gastrointestinal intolerance (15%).
    2 context sentences
    Summary · context
    We conducted a retrospective, multicenter observational study of adults with T2DM hospitalized for ACS between January 2022 and December 2024 and discharged with a prescription for semaglutide.
    Summary · context
    A total of 60 patients (mean age 61.1 ± 10.8 years, 73% male) were included.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes after acute coronary syndrome, body weight decreased by 4.7 ± 1.6 kg on semaglutide at the first follow-up.

    In plain wordsAfter a heart event, adults with type 2 diabetes lost 4.7 kg on average on semaglutide at the first follow-up.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change at first follow-up
    Study

    n = 60

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    lowest dose · injectable (83.3%) or oral (16.7%) · 108 ± 39 daysAs given in this study (human).

    Measurements

    Body weight decrease
    4.7 kg
    first follow-up

    Source sentences

    Summary
    Body weight decreased by 4.7 ± 1.6 kg
    2 context sentences
    Summary · context
    We conducted a retrospective, multicenter observational study of adults with T2DM hospitalized for ACS between January 2022 and December 2024 and discharged with a prescription for semaglutide.
    Summary · context
    A total of 60 patients (mean age 61.1 ± 10.8 years, 73% male) were included.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes after acute coronary syndrome, BMI decreased by 1.7 ± 0.6 kg/m2 on semaglutide at the first follow-up.

    In plain wordsAfter a heart event, adults with type 2 diabetes had a lower body mass index on semaglutide at the first follow-up.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI change at first follow-up
    Study

    n = 60

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    lowest dose · injectable (83.3%) or oral (16.7%) · 108 ± 39 daysAs given in this study (human).

    Measurements

    BMI decrease
    1.7 kg/m2
    first follow-up

    Source sentences

    Summary
    BMI decreased by 1.7 ± 0.6 kg/m2
    2 context sentences
    Summary · context
    We conducted a retrospective, multicenter observational study of adults with T2DM hospitalized for ACS between January 2022 and December 2024 and discharged with a prescription for semaglutide.
    Summary · context
    A total of 60 patients (mean age 61.1 ± 10.8 years, 73% male) were included.
  5. 05HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes after acute coronary syndrome, HbA1c improved from 64.3 ± 18.2 to 49.6 ± 10.4 mmol/mol on semaglutide at the first follow-up.

    In plain wordsAfter a heart event, blood sugar control (HbA1c) improved in adults with type 2 diabetes on semaglutide at the first follow-up.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c at first follow-up
    Study

    n = 60

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    lowest dose · injectable (83.3%) or oral (16.7%) · 108 ± 39 daysAs given in this study (human).

    Measurements

    HbA1c baseline
    64.3 mmol/mol
    baseline
    HbA1c
    49.6 mmol/mol
    first follow-up

    Source sentences

    Summary
    HbA1c improved from 64.3 ± 18.2 to 49.6 ± 10.4 mmol/mol.
    2 context sentences
    Summary · context
    We conducted a retrospective, multicenter observational study of adults with T2DM hospitalized for ACS between January 2022 and December 2024 and discharged with a prescription for semaglutide.
    Summary · context
    A total of 60 patients (mean age 61.1 ± 10.8 years, 73% male) were included.
  6. 06HumanObservational studySafety outcome

    No cardiovascular events were reported in adults with type 2 diabetes starting semaglutide after acute coronary syndrome.

    In plain wordsAfter a heart event, no new heart or blood vessel events were reported in adults who started semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeCardiovascular events
    Study

    n = 60

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    lowest dose · injectable (83.3%) or oral (16.7%)As given in this study (human).

    Source sentences

    Summary
    No cardiovascular events, renal decline, or pancreatic events were reported.
    2 context sentences
    Summary · context
    We conducted a retrospective, multicenter observational study of adults with T2DM hospitalized for ACS between January 2022 and December 2024 and discharged with a prescription for semaglutide.
    Summary · context
    A total of 60 patients (mean age 61.1 ± 10.8 years, 73% male) were included.
  7. 07HumanObservational studySafety outcome

    No renal decline was reported in adults with type 2 diabetes starting semaglutide after acute coronary syndrome.

    In plain wordsAfter a heart event, no kidney function decline was reported in adults who started semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeRenal decline
    Study

    n = 60

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    lowest dose · injectable (83.3%) or oral (16.7%)As given in this study (human).

    Source sentences

    Summary
    No cardiovascular events, renal decline, or pancreatic events were reported.
    2 context sentences
    Summary · context
    We conducted a retrospective, multicenter observational study of adults with T2DM hospitalized for ACS between January 2022 and December 2024 and discharged with a prescription for semaglutide.
    Summary · context
    A total of 60 patients (mean age 61.1 ± 10.8 years, 73% male) were included.
  8. 08HumanObservational studySafety outcome

    No pancreatic events were reported in adults with type 2 diabetes starting semaglutide after acute coronary syndrome.

    In plain wordsAfter a heart event, no pancreas problems were reported in adults who started semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changePancreatic events
    Study

    n = 60

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    lowest dose · injectable (83.3%) or oral (16.7%)As given in this study (human).

    Source sentences

    Summary
    No cardiovascular events, renal decline, or pancreatic events were reported.
    2 context sentences
    Summary · context
    We conducted a retrospective, multicenter observational study of adults with T2DM hospitalized for ACS between January 2022 and December 2024 and discharged with a prescription for semaglutide.
    Summary · context
    A total of 60 patients (mean age 61.1 ± 10.8 years, 73% male) were included.
  9. 09HumanObservational studyOther

    At the second follow-up, 97.4% of the 39 patients were still on semaglutide.

    In plain wordsAfter a heart event, 97.4% of the adults followed longer were still taking semaglutide at the second follow-up.

    Peptide
    Semaglutide
    Outcome
    Not applicableTreatment persistence at second follow-up
    Study

    n = 39

    Outcome group
    Treatment adherence and retention · Cardiovascular
    Studied dose
    lowest dose · injectable (83.3%) or oral (16.7%) · 278 ± 60 daysAs given in this study (human).

    Measurements

    Persistence
    97.4%
    second follow-up

    Source sentences

    Summary
    At the second follow-up (278 ± 60 days, n = 39), 97.4% were still on semaglutide.
    2 context sentences
    Summary · context
    We conducted a retrospective, multicenter observational study of adults with T2DM hospitalized for ACS between January 2022 and December 2024 and discharged with a prescription for semaglutide.
    Summary · context
    A total of 60 patients (mean age 61.1 ± 10.8 years, 73% male) were included.
  10. 10HumanObservational studyEfficacy outcome

    At the second follow-up, additional weight loss of -2.6 ± 3.8 kg was observed on semaglutide.

    In plain wordsAfter a heart event, adults with type 2 diabetes lost further weight on semaglutide at the second follow-up.

    Peptide
    Semaglutide
    Outcome
    DecreaseAdditional body weight change at second follow-up
    Study

    n = 39

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    lowest dose · injectable (83.3%) or oral (16.7%) · 278 ± 60 daysAs given in this study (human).

    Measurements

    Additional weight change
    −2.6 kg
    second follow-up

    Source sentences

    Summary
    Additional weight loss (-2.6 ± 3.8 kg
    2 context sentences
    Summary · context
    We conducted a retrospective, multicenter observational study of adults with T2DM hospitalized for ACS between January 2022 and December 2024 and discharged with a prescription for semaglutide.
    Summary · context
    A total of 60 patients (mean age 61.1 ± 10.8 years, 73% male) were included.
  11. 11HumanObservational studyEfficacy outcome

    At the second follow-up, a further HbA1c reduction to 40.5 ± 18.6 mmol/mol was observed on semaglutide.

    In plain wordsAfter a heart event, blood sugar control (HbA1c) improved further on semaglutide at the second follow-up.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c at second follow-up
    Study

    n = 39

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    lowest dose · injectable (83.3%) or oral (16.7%) · 278 ± 60 daysAs given in this study (human).

    Measurements

    HbA1c
    40.5 mmol/mol
    second follow-up

    Source sentences

    Summary
    further HbA1c reduction (40.5 ± 18.6 mmol/mol
    2 context sentences
    Summary · context
    We conducted a retrospective, multicenter observational study of adults with T2DM hospitalized for ACS between January 2022 and December 2024 and discharged with a prescription for semaglutide.
    Summary · context
    A total of 60 patients (mean age 61.1 ± 10.8 years, 73% male) were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.